Skip to main content
SpringerLink
Log in

Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion

  • Melanomas
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 29 February 2016

Abstract

Background

The incidence of malignant melanoma is increasing, and up to 5 % of patients will experience in-transit metastases. Normally, the initial treatment is surgical excision, but when not possible, locoregional treatment options such as isolated limb perfusion (ILP) are an alternative. This study aimed to assess health-related quality of life (HRQoL) prospectively for patients whose in-transit metastases is treated with ILP. More specifically, the study aimed to describe HRQoL for patients with in-transit extremity melanoma metastases, to describe changes in HRQoL after ILP, and to correlate HRQoL with local toxicity and clinical response after ILP.

Methods

The Functional Assessment of Cancer Therapy–Melanoma (FACT-M) consists of 51 items comprising the Functional Assessment of Cancer Therapy–General (FACT-G), the melanoma subscale , and the melanoma surgery scale. Forty-five patients answered the FACT-M questionnaire before ILP (52 procedures) and at 3, 6 and 12 months after ILP. Response and toxicity were analyzed and correlated with the changes in the HRQoL of the patients.

Results

Patients with in-transit metastasis have an HRQoL mainly influenced by tumor burden, defined as more or <10 tumors (FACT-M: 142.5 vs. 128.4 points; p = 0.02). After ILP, there was a trend toward a decrease in FACT-G (+0.1 vs. −7.3 points; p = 0.05) and FACT-M (+1.6 vs. −8.9 points; p = 0.08) when Wieberdink classifications 1–2 and 3–4 were compared at 3 months. A significant difference in FACT-G (+1.0 vs. −13.0 points; p = 0.04) was observed 12 months after ILP as well as a trend for FACT-M (+1.7 vs. −14.6 points; p = 0.08) when the patients who had a complete response were compared with those who did not.

Conclusion

This study found that patients with in-transit metastases have an HRQoL mainly influenced by tumor burden. After ILP, there is an initial decrease in HRQoL due to local toxicity. After 12 months, the patients with a complete response maintained an HRQoL at baseline level, strengthening the use of ILP as a palliative treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Socialstyrelsen. Cancer Incidence in Sweden 2013. Socialstyrelsen, Stockholm, 2014.

  2. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol. 2009;20(Suppl 6):vi51–vi8.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Beutel ME, Fischbeck S, Binder H, Blettner M, Brahler E, Emrich K, et al. Depression, anxiety, and quality of life in long-term survivors of malignant melanoma: a register-based cohort study. PLoS One. 2015;10(1):e0116440.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Al-Shakhli H, Harcourt D, Kenealy J. Psychological distress surrounding diagnosis of malignant and nonmalignant skin lesions at a pigmented lesion clinic. J Plast Reconstr Aesth Surg. 2006;59:479–86.

    Article  CAS  Google Scholar 

  5. Read RL, Haydu L, Saw RP, Quinn MJ, Shannon K, Spillane AJ, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22:475–81.

    Article  PubMed  Google Scholar 

  6. Pawlik TM, Ross MI, Johnson MM, Schacherer CW, McClain DM, Mansfield PF, et al. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005;12:587–96.

    Article  PubMed  Google Scholar 

  7. 7. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. Springer, New York, 2010.

    Google Scholar 

  8. Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. Oncologist. 2010;15:416–27.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Olofsson Bagge R, Mattsson J, Hafstrom L (2014) Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities: long-term follow-up of a randomised trial. Int J Hyperthermia. 30:295–8.

    Article  CAS  PubMed  Google Scholar 

  10. Thompson JF, Agarwala SS, Smithers BM, Ross MI, Scoggins CR, Coventry BJ, et al. Phase 2 study of intralesional PV-10 in refractory metastatic melanoma. Ann Surg Oncol. 2015;22:2135–42.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8.

    Article  CAS  PubMed  Google Scholar 

  12. Robinson DW Jr, Cormier JN, Zhao N, Uhlar CM, Revicki DA, Cella D. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study. Melanoma Res. 2012;22:54–62.

    Article  PubMed  Google Scholar 

  13. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, et al. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008;112:2249–57.

    Article  PubMed  Google Scholar 

  14. Jiang BS, Speicher PJ, Thomas S, Mosca PJ, Abernethy AP, Tyler DS. Quality of life after isolated limb infusion for in-transit melanoma of the extremity. Ann Surg Oncol. 2015;22:1694–700.

    Article  PubMed  Google Scholar 

  15. Noorda EM, van Kreij RH, Vrouenraets BC, Nieweg OE, Muller M, Kroon BB, Aronson NK. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. Eur J Surg Oncol. 2007;33:776–82.

    Article  CAS  PubMed  Google Scholar 

  16. McClaine RJ, Giglia JS, Ahmad SA, McCoy SJ, Sussman JJ. Quality-of-life outcomes after isolated limb infusion. Ann Surg Oncol. 2012;19:1373–8.

    Article  PubMed  Google Scholar 

  17. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization, Geneva, 1979, 45 p.

    Google Scholar 

  18. Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthuis GA. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905–10.

    Article  CAS  PubMed  Google Scholar 

  19. Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Profess. 2005;28:192–211.

    Article  Google Scholar 

  20. Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN. Evaluating minimal important differences for the FACT-Melanoma quality-of-life questionnaire. Value Health. 2009;12:1144–50.

    Article  PubMed  Google Scholar 

  21. Vrouenraets BC, Hart GA, Eggermont AM, Klaase JM, van Geel BN, Nieweg OE, et al. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg. 1999;188:522–30.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

This study was supported by a grant from the Gothenburg Medical Society. We also express our sincere gratitude to Mrs. Ulrika Hylén Nilsson for administrating the questionnaires. J. Stubbs, MSc, reviewed the English.

Conflict of Interest

There are no conflicts of interest.

Author information

Author notes

    Authors and Affiliations

    1. Centre for Ethics, Law and Mental Health (CELAM), University of Gothenburg, Gothenburg, Sweden

      Ann-Sophie Lindqvist Bagge PhD

    2. Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden

      Ann-Sophie Lindqvist Bagge PhD, Ilan Ben-Shabat, Valerio Belgrano MD & Roger Olofsson Bagge MD, PhD

    Authors
    1. Ann-Sophie Lindqvist Bagge PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ilan Ben-Shabat
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Valerio Belgrano MD
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Roger Olofsson Bagge MD, PhD
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Roger Olofsson Bagge MD, PhD.

    Additional information

    Ann-Sophie Lindqvist Bagge and Ilan Ben-Shabat have contributed equally to this work

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Bagge, AS.L., Ben-Shabat, I., Belgrano, V. et al. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion. Ann Surg Oncol 23, 2062–2069 (2016). https://doi.org/10.1245/s10434-016-5103-9

    Download citation

    • Received:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1245/s10434-016-5103-9

    Keywords

    Search

    Navigation